Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome
Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome
复制标题
DOI：
10.1016/s0140-6736(03)14072-x
复制
发表时间：
2003-08-09
期刊：
影响因子：
168.9
通讯作者：
Trompeter, RS
中科院分区：
文献类型：
--
作者：
Abeyagunawardena, AS;Goldblatt, D;Trompeter, RS
1999年11月，英国所有18岁以下的儿童都接种了新引进的脑膜炎球菌C结合疫苗（MCCV）。在106例肾病综合征患者的队列中，在接种疫苗前12个月内有63例复发，在接种疫苗后的同等时间内有96例复发（p=0.009）。MCCV治疗后肾病综合征复发率明显增加。是否给这些孩子接种疫苗需要慎重考虑。
In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.